Search results
Results From The WOW.Com Content Network
Brian Wallach (born October 9, 1980) is an American businessman, lawyer, and amyotrophic lateral sclerosis (ALS) research and patient advocate. He became known for his activism after being diagnosed with ALS in 2017. [1] Since then, Wallach has founded a nonprofit, I AM ALS, and a telemedicine company, Synapticure.
He was awarded the Congressional Gold Medal for his contributions to ALS awareness. Activist Brian Wallach's advocacy through his foundation I AM ALS saw the Accelerating Access to Critical Therapies for ALS Act signed into law by President Joe Biden in 2021. Jason Becker (born 1969), American musician, songwriter and composer. [1]
ALS is the most common form of the motor neuron diseases. [8] ALS often presents in its early stages with gradual muscle stiffness, twitches, weakness, and wasting. [3] Motor neuron loss typically continues until the abilities to eat, speak, move, and, lastly, breathe are all lost. [3]
Articles relating to amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND) or Lou Gehrig's disease. It is a specific disease which causes the death of neurons controlling voluntary muscles. ALS is characterized by stiff muscles, muscle twitching, and gradually worsening weakness due to muscles decreasing in size.
Associated with 3-5% of ALS cases; considered an ALS risk gene rather than a causative gene as of 2018. [1] ALS25: 617921: KIF5A: 12q13.3 autosomal dominant 2018 FTD-ALS1: 105550: C9orf72: 9p21.2 autosomal dominant 2011 The gene most commonly associated with ALS, C9orf72 accounts for 40% of fALS cases and 7% of sALS cases. [2] FTD-ALS2: 615911 ...
The ALS Association is an American nonprofit organization that funds global amyotrophic lateral sclerosis (ALS) research, provides care services and programs to people affected by ALS through its nationwide network of clinical care centers, and works with ALS advocates around the country for state and federal policies that serve people living with amyotrophic lateral sclerosis (ALS), also ...
Familial ALS is the most studied; however, a new technique that was recently introduced is the use of induced pluripotent stem cells (iPSC). [2] In this study the researcher can isolate skin fibroblast from a patient with familial or sporadic ALS and reprogram them into motor neuron to study ALS. [ 2 ]
The institute has raised and spent more than $100 million on research into effective treatments for ALS and practices open-source science. [19] After the discovery that the multiple sclerosis drug Gilenya might also be a treatment for ALS, the Institute enrolled 30 people in a Phase 2A clinical trial the drug in 2013, though it did not progress further.